Jump Financial LLC Has $36.15 Million Position in Thermo Fisher Scientific Inc. $TMO

Key Points

• Jump Financial LLC has increased its stake in Thermo Fisher Scientific by 48.2%, acquiring an additional 23,643 shares to bring its total holdings to 72,654 shares valued at approximately $36 million.
• Several analysts have recently revised their ratings and price targets for Thermo Fisher Scientific, with Argus lowering its target from $620 to $470, while Robert W. Baird raised its target from $553 to $567.
• Thermo Fisher Scientific's most recent quarterly earnings report showed an EPS of $5.36, exceeding analyst expectations, and the company has set guidance for Q3 2025 ranging from $5.460 to $5.510.

Jump Financial LLC grew its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 48.2% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 72,654 shares of the medical research company's stock after acquiring an additional 23,643 shares during the quarter. Thermo Fisher Scientific accounts for about 0.5% of Jump Financial LLC's holdings, making the stock its 13th largest position. Jump Financial LLC's holdings in Thermo Fisher Scientific were worth $36,153,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. GAMMA Investing LLC increased its holdings in Thermo Fisher Scientific by 60,610.9% during the 1st quarter. GAMMA Investing LLC now owns 2,419,331 shares of the medical research company's stock valued at $1,203,859,000 after purchasing an additional 2,415,346 shares in the last quarter. Nuveen LLC acquired a new stake in Thermo Fisher Scientific during the 1st quarter valued at $532,360,000. Kovitz Investment Group Partners LLC increased its holdings in Thermo Fisher Scientific by 1,905.4% during the 4th quarter. Kovitz Investment Group Partners LLC now owns 903,232 shares of the medical research company's stock valued at $469,889,000 after purchasing an additional 858,193 shares in the last quarter. Farallon Capital Management LLC increased its holdings in Thermo Fisher Scientific by 73.8% during the 4th quarter. Farallon Capital Management LLC now owns 1,233,256 shares of the medical research company's stock valued at $641,577,000 after purchasing an additional 523,800 shares in the last quarter. Finally, Sarasin & Partners LLP acquired a new stake in Thermo Fisher Scientific during the 1st quarter valued at $242,991,000. Institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Trading Down 0.0%

Shares of Thermo Fisher Scientific stock traded down $0.01 during trading hours on Wednesday, hitting $488.47. The company's stock had a trading volume of 1,287,770 shares, compared to its average volume of 2,461,156. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $627.88. The stock has a 50 day moving average of $446.71 and a 200 day moving average of $455.47. The company has a market capitalization of $184.45 billion, a PE ratio of 28.25, a price-to-earnings-growth ratio of 2.62 and a beta of 0.74. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The company had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. During the same period in the prior year, the company earned $5.37 earnings per share. The company's revenue for the quarter was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.4%. Thermo Fisher Scientific's payout ratio is presently 9.95%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on TMO shares. Barclays boosted their target price on Thermo Fisher Scientific from $450.00 to $490.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 24th. HSBC restated a "hold" rating and set a $510.00 target price on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Evercore ISI dropped their target price on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a research report on Tuesday, July 8th. Wall Street Zen downgraded Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research report on Sunday, August 10th. Finally, Hsbc Global Res downgraded Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 24th. Sixteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $593.00.

Insider Buying and Selling

In other news, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the completion of the transaction, the chief executive officer directly owned 115,174 shares of the company's stock, valued at $57,697,567.04. This represents a 7.99% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the company's stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the transaction, the executive vice president directly owned 22,367 shares of the company's stock, valued at $10,735,712.66. This represents a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 28,896 shares of company stock worth $13,603,438. Insiders own 0.33% of the company's stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.